187 related articles for article (PubMed ID: 37817743)
21. Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.
McGarry ME; Gibb ER; Oates GR; Schechter MS
Paediatr Respir Rev; 2022 Jun; 42():35-42. PubMed ID: 35277357
[TBL] [Abstract][Full Text] [Related]
22. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
23. The implications of CFTR structural studies for cystic fibrosis drug development.
Callebaut I; Hoffmann B; Mornon JP
Curr Opin Pharmacol; 2017 Jun; 34():112-118. PubMed ID: 29096277
[TBL] [Abstract][Full Text] [Related]
24. Emerging medicines to improve the basic defect in cystic fibrosis.
Fajac I; Sermet-Gaudelus I
Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
[TBL] [Abstract][Full Text] [Related]
25. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
[TBL] [Abstract][Full Text] [Related]
26. Pulmonology: CFTR modulators for cystic fibrosis.
Bertoncini E; Colomb-Lippa D
JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
[No Abstract] [Full Text] [Related]
27. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
28. CFTR: cystic fibrosis and beyond.
Mall MA; Hartl D
Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
[TBL] [Abstract][Full Text] [Related]
29. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
30. Lung clearance index response in patients with CF with class III CFTR mutations.
Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F
Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510
[No Abstract] [Full Text] [Related]
31. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
32. [Genotypes of cystic fibrosis (CF) reported in the world and polymorphisms of cystic fibrosis transmembrane conductance regulator (CFTR) gene in Japanese].
Wang W; Okayama H; Shirato K
Nihon Rinsho; 1996 Feb; 54(2):525-32. PubMed ID: 8838109
[TBL] [Abstract][Full Text] [Related]
33. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
[TBL] [Abstract][Full Text] [Related]
34. CFTR: New insights into structure and function and implications for modulation by small molecules.
Kleizen B; Hunt JF; Callebaut I; Hwang TC; Sermet-Gaudelus I; Hafkemeyer S; Sheppard DN
J Cyst Fibros; 2020 Mar; 19 Suppl 1():S19-S24. PubMed ID: 31759907
[TBL] [Abstract][Full Text] [Related]
35. The impact of CFTR modulators on bone health.
Clarke E; Moore F; Gallagher A; Thomson S
Pediatr Pulmonol; 2023 Apr; 58(4):1256. PubMed ID: 36635953
[No Abstract] [Full Text] [Related]
36. Important steps in the journey to highly effective CFTR modulator access for people with CF.
VanDevanter DR; Mayer-Hamblett N
J Cyst Fibros; 2019 Sep; 18(5):577-578. PubMed ID: 31500809
[No Abstract] [Full Text] [Related]
37. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.
Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M
PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274
[TBL] [Abstract][Full Text] [Related]
38. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.
Pedemonte N; Diena T; Caci E; Nieddu E; Mazzei M; Ravazzolo R; Zegarra-Moran O; Galietta LJ
Mol Pharmacol; 2005 Dec; 68(6):1736-46. PubMed ID: 16150931
[TBL] [Abstract][Full Text] [Related]
39. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
Edmondson C; Course CW; Doull I
Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
[TBL] [Abstract][Full Text] [Related]
40. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
